Fig. 4

Kaplan–Meier survival curves of patients in antiviral and non-antiviral subgroups after stratification with baseline HBV DNA loads. a OS rates among the four subgroups of patients (log-rank test: subgroup 3 vs. subgroup 1, P = 0.001; subgroup 3 vs. subgroup 2, P < 0.001; subgroup 3 vs. subgroup 4, P = 0.001; subgroup 1 vs. subgroup 2, P = 0.142; subgroup 1 vs. subgroup 4, P = 0.837; subgroup 2 vs. subgroup 4, P = 0.202). b DFS rates among the four subgroups of patients (subgroup 3 vs. subgroup 1, P = 0.041; subgroup 3 vs. subgroup 2, P = 0.009; subgroup 3 vs. subgroup 4, P = 0.000; subgroup 1 vs. subgroup 2, P = 0.292; subgroup 1 vs. subgroup 4, P = 0.082; subgroup 2 vs. subgroup 4, P = 0.777). [Note: (1) Subgroup 1, antiviral treatment with baseline hepatitis B virus (HBV) DNA ≥2000 IU/mL (n = 141); (2) Subgroup 2, antiviral treatment with baseline HBV DNA <2000 IU/mL or undetectable (n = 51); (3) Subgroup 3, no antiviral treatment with baseline HBV DNA ≥2000 IU/mL (n = 99); and (4) Subgroup 4, no antiviral treatment with baseline HBV DNA <2000 IU/mL or undetectable (n = 154).]